Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to Buy at Needham & Company LLC

Needham & Company LLC upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research report sent to investors on Friday morning, MarketBeat.com reports. The firm currently has $46.00 price objective on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently commented on the company. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.80.

Collegium Pharmaceutical Stock Down 1.3 %

Shares of Collegium Pharmaceutical stock opened at $32.91 on Friday. Collegium Pharmaceutical has a twelve month low of $28.39 and a twelve month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company’s 50 day moving average is $30.57 and its 200 day moving average is $34.04. The company has a market cap of $1.06 billion, a price-to-earnings ratio of 14.19 and a beta of 0.82.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. TD Private Client Wealth LLC lifted its holdings in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. Foundry Partners LLC raised its position in shares of Collegium Pharmaceutical by 3.3% during the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the period. CWM LLC lifted its stake in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 792 shares during the period. Finally, Harbor Capital Advisors Inc. increased its stake in Collegium Pharmaceutical by 4.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company’s stock worth $908,000 after buying an additional 983 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.